UC Davis-led trial of Zynlonta combination in DLBCL marked suspended as of Nov. 16 updateNov 16Trial updateADC Therapeutics SAloncastuximab tesirine
ADC Therapeutics reports Q3 2026 results, restructuring extends cash runway into 2029Nov 9Quarterly updateADC Therapeutics SAloncastuximab tesirine
ADC Therapeutics restructures finances with $86.6 million private placementOct 13FinancingADC Therapeutics SA
ADC Therapeutics reweighs ZYNLONTA path after FDA raises LOTIS-5 safety concernsAug 13Quarterly updateADC Therapeutics SAloncastuximab tesirine